GR1001368B - Φαρμακευτικοί φορείς. - Google Patents
Φαρμακευτικοί φορείς.Info
- Publication number
- GR1001368B GR1001368B GR920100425A GR920100425A GR1001368B GR 1001368 B GR1001368 B GR 1001368B GR 920100425 A GR920100425 A GR 920100425A GR 920100425 A GR920100425 A GR 920100425A GR 1001368 B GR1001368 B GR 1001368B
- Authority
- GR
- Greece
- Prior art keywords
- pharmaceutical agents
- pharmaceutical
- agents
- methoxy
- natural form
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Φυσική μορφή του (R)-3-μεθοξυ-4-ω
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR92100425 | 1992-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
GR1001368B true GR1001368B (el) | 1993-10-29 |
Family
ID=10941195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR920100425A GR1001368B (el) | 1992-10-08 | 1992-10-08 | Φαρμακευτικοί φορείς. |
Country Status (1)
Country | Link |
---|---|
GR (1) | GR1001368B (el) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0432984A2 (en) * | 1989-12-11 | 1991-06-19 | Zeneca Limited | Carbamoyl derivatives |
EP0490648A1 (en) * | 1990-12-12 | 1992-06-17 | Zeneca Limited | Pharmaceutical agents |
EP0490649A1 (en) * | 1990-12-12 | 1992-06-17 | Zeneca Limited | A physical form of N-[4-[5-(cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulfonamide, a process for its preparation and pharmaceutical compositions containing it |
-
1992
- 1992-10-08 GR GR920100425A patent/GR1001368B/el not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0432984A2 (en) * | 1989-12-11 | 1991-06-19 | Zeneca Limited | Carbamoyl derivatives |
EP0490648A1 (en) * | 1990-12-12 | 1992-06-17 | Zeneca Limited | Pharmaceutical agents |
EP0490649A1 (en) * | 1990-12-12 | 1992-06-17 | Zeneca Limited | A physical form of N-[4-[5-(cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulfonamide, a process for its preparation and pharmaceutical compositions containing it |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR890100838A (el) | Νέα ?εραπευτικώς δραστική ένωσις και μέ?οδος για την παραγωγή της. | |
DE69429359D1 (de) | Orale zubereitungen von antimykotika | |
DK42093D0 (da) | Administrationsmetode | |
MX9205981A (es) | Administracion transdermica de melatonina. | |
NO930677L (no) | Farmasoeytiske forbindelser | |
KR950700323A (ko) | 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 아미노아세틸머캅토아세틸아미드 유도체(Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE) | |
DE69119539D1 (de) | Ersetzung von Hauptleitungen | |
IT1285770B1 (it) | Composti corticoidei | |
MX9302116A (es) | Compuestos azabiciclo. | |
FR2686425B1 (fr) | Source sismique de puits. | |
ATE203519T1 (de) | Chinolinderivate als antimalariamittel | |
DK0736029T3 (da) | Antikonvulsive pseudofructopyranosesulfamater | |
NO931008D0 (no) | Farmasoeytiske forbindelser | |
ES2105605T3 (es) | Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas. | |
DE69230224D1 (de) | Potenzierung von nmda-antagonisten | |
ATE228760T1 (de) | Thrombininhibitoren | |
ATE57526T1 (de) | P-acylaminobenzamide. | |
GR1001368B (el) | Φαρμακευτικοί φορείς. | |
ATE90195T1 (de) | Minoxidil-gel. | |
FI913285A (fi) | Svavelsubstituerade mevinsyraderivat. | |
YU48719B (sh) | Lizin so 6-hloro-5-fluoro-3-(2-tenoil)-2-oksindol-1-karboksamida | |
DE69614552D1 (de) | MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE | |
TR199701011A2 (xx) | 1-karba-(detia)-sefalosforin t�revleri. | |
NO934345L (no) | Seismisk kilde | |
TR199801087T2 (xx) | 4,10 �- diasetoksi-2alfa-Benzoiloksi- 5 �, 20 epoksi-1- hidroksi-9- okso-19- norsiklopropa(G) taks-11- en- 13alfa-il |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ML | Lapse due to non-payment of fees |